Search
Lincoln, NE Paid Clinical Trials
A listing of 168 clinical trials in Lincoln, NE actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
109 - 120 of 168
There are currently 168 clinical trials in Lincoln, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including Saint Elizabeth Regional Medical Center, Celerion, Cancer Resource Center - Lincoln and Nebraska Cancer Research Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Nebraska Hematology and Oncology, Lincoln, Nebraska +1 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Research Site, Lincoln, Nebraska
Conditions: Metastatic Non-small Cell Lung Cancer
Multi-Site Feasibility Testing of the Ventricular Assist Device Anticipatory Guidance Tool
Recruiting
There are a variety of educational documents available to help in a participant's decision for VAD implant, however there is little information available to potential participants to help understand areas of satisfaction and concern following a VAD implant as various time points. The investigators want to provide better patient care through increased education and awareness beyond surgical outcomes and contribute to patient understanding of "what to expect" following a VAD implant.
The investig... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
03/10/2025
Locations: Bryan Heart, Lincoln, Nebraska
Conditions: Ventricular Assist Device, Advanced Heart Failure, Anticipatory Guidance
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of t... Read More
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
03/07/2025
Locations: Meridian Clinical Research, Lincoln, Nebraska +1 locations
Conditions: SARS-CoV-2
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Recruiting
An open label phase 3 study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Sunpharma Site no 27, Lincoln, Nebraska
Conditions: Psoriatic Arthritis
Amplatzer Amulet LAAO Vs. NOAC
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy.
The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Bryan Heart, Lincoln, Nebraska
Conditions: Atrial Fibrillation, Stroke, Bleeding
[18F]PI-2620 Phase 3 Histopathological Study
Recruiting
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/21/2025
Locations: Be Well Clinical Studies, Lincoln, Nebraska
Conditions: Alzheimer Disease
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Recruiting
The purpose of this study is to determine if the use of image-guided, endovascular therapy (EVT) is an effective strategy with which to reduce Post Thrombotic Syndrome (PTS) disease severity and improve quality of life in patients with established disabling iliac-obstructive post thrombotic syndrome (DIO-PTS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: St. Elizabeth's Hospital, Lincoln, Nebraska
Conditions: Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: NHO-Revive Research Institute, LLC - 1152, Lincoln, Nebraska
Conditions: Non Small Cell Lung Cancer
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
02/07/2025
Locations: Home-based telemedicine, Lincoln, Nebraska
Conditions: Chronic Granulomatous Disease (CGD)
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects with Narcolepsy Type 2
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/05/2025
Locations: Alkermes Investigator Site, Lincoln, Nebraska
Conditions: Narcolepsy Type 2
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institution - 0060, Lincoln, Nebraska
Conditions: Multiple Myeloma
109 - 120 of 168